Aethlon Medical, Inc. (NASDAQ:AEMD – Get Rating) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 9,500 shares, a decline of 69.2% from the March 31st total of 30,800 shares. Based on an average daily volume of 73,000 shares, the days-to-cover ratio is currently 0.1 days.
A number of institutional investors have recently modified their holdings of AEMD. BlackRock Inc. raised its position in Aethlon Medical by 771.7% in the third quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock worth $282,000 after acquiring an additional 64,691 shares in the last quarter. Geode Capital Management LLC increased its stake in Aethlon Medical by 32.3% in the 3rd quarter. Geode Capital Management LLC now owns 136,451 shares of the medical equipment provider’s stock worth $526,000 after purchasing an additional 33,330 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Aethlon Medical in the 3rd quarter worth about $196,000. Dimensional Fund Advisors LP purchased a new position in Aethlon Medical in the 3rd quarter worth about $397,000. Finally, Jane Street Group LLC purchased a new position in Aethlon Medical in the 3rd quarter worth about $101,000. Hedge funds and other institutional investors own 7.71% of the company’s stock.
A number of brokerages recently weighed in on AEMD. Maxim Group cut their price objective on shares of Aethlon Medical from $11.00 to $4.00 in a research note on Tuesday, February 15th. StockNews.com began coverage on shares of Aethlon Medical in a research note on Wednesday. They set a “sell” rating on the stock.
Aethlon Medical (NASDAQ:AEMD – Get Rating) last issued its quarterly earnings results on Monday, February 14th. The medical equipment provider reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). Aethlon Medical had a negative return on equity of 45.91% and a negative net margin of 2,823.49%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.26 million. During the same quarter last year, the firm posted ($0.20) earnings per share. Equities research analysts anticipate that Aethlon Medical will post -0.56 EPS for the current fiscal year.
Aethlon Medical Company Profile (Get Rating)
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.